Ten post jest także dostępny w języku: polski
On March 15, the Supervisory Board of Selvita SA decided to appoint Steffen Heeger to the position of a member of the Management Board of the company. The decision comes into force on 1 April 2019. Heeger will be responsible for clinical development as well as medical and regulatory issues related to oncology projects as a member of the Board of Directors.
Steffen Heeger has been with Selvita since February 2018. He then took up the position of Chief Medical Officer. Previously, he served as Vice President and Director of Development and Operations at Morphosys AG. It is a German biotechnology company specializing in hematopoietic system tumors. He was responsible for developing and implementing a clinical strategy for haematology and oncology products.
He also worked for Merck Serono, a global pharmaceutical company. For nine years, he led the team responsible for clinical development of the Erbitux drug for the treatment of patients with metastatic colorectal cancer.
Selvita is a Polish biotech company. It operates mainly in the field of oncology. It also operates in the segments of chemistry, contract biology and bioinformatics. In the first three quarters of 2018, the company’s revenue amounted to PLN 56.6 million, compared to PLN 48.3 million in the previous year.